Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based Basilea Pharmaceutica has started second randomized, double-blind, placebo-controlled Phase I trial to evaluate its new sulfactam antibiotic BAL30072 against multidrug-resistant Gram-negative bacteria.
Subscribe to our email newsletter
The trial is aimed to investigate the safety, pharmacokinetics and tolerability of BAL30072 following multiple ascending intravenous infusions in healthy volunteers.
BAL30072 demonstrated safety and tolerability profile in a single ascending dose Phase I trial and has also showed dose-proportional pharmacokinetic properties.
The sulfactam antibiotic BAL30072 in in vitro and in vivo models has demonstrated potent bactericidal activity against a broad range of multidrug-resistant Gram-negative pathogens such as Pseudomonas or Acinetobacter species.
Basilea CEO Anthony Man said the company expects to complete the second study in the first half of 2012.